These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24164572)

  • 1. Benchmarking in vitro covalent binding burden as a tool to assess potential toxicity caused by nonspecific covalent binding of covalent drugs.
    Dahal UP; Obach RS; Gilbert AM
    Chem Res Toxicol; 2013 Nov; 26(11):1739-45. PubMed ID: 24164572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction.
    Bauman JN; Kelly JM; Tripathy S; Zhao SX; Lam WW; Kalgutkar AS; Obach RS
    Chem Res Toxicol; 2009 Feb; 22(2):332-40. PubMed ID: 19161298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans.
    Masubuchi N; Makino C; Murayama N
    Chem Res Toxicol; 2007 Mar; 20(3):455-64. PubMed ID: 17309281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding.
    Nakayama S; Atsumi R; Takakusa H; Kobayashi Y; Kurihara A; Nagai Y; Nakai D; Okazaki O
    Drug Metab Dispos; 2009 Sep; 37(9):1970-7. PubMed ID: 19487250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug discovery for a new generation of covalent drugs.
    Kalgutkar AS; Dalvie DK
    Expert Opin Drug Discov; 2012 Jul; 7(7):561-81. PubMed ID: 22607458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose.
    Obach RS; Kalgutkar AS; Soglia JR; Zhao SX
    Chem Res Toxicol; 2008 Sep; 21(9):1814-22. PubMed ID: 18690722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of new chemical entities with decreased potential for adverse drug reactions.
    Park KB; Dalton-Brown E; Hirst C; Williams DP
    Eur J Pharmacol; 2006 Nov; 549(1-3):1-8. PubMed ID: 16979156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors.
    Flanagan ME; Abramite JA; Anderson DP; Aulabaugh A; Dahal UP; Gilbert AM; Li C; Montgomery J; Oppenheimer SR; Ryder T; Schuff BP; Uccello DP; Walker GS; Wu Y; Brown MF; Chen JM; Hayward MM; Noe MC; Obach RS; Philippe L; Shanmugasundaram V; Shapiro MJ; Starr J; Stroh J; Che Y
    J Med Chem; 2014 Dec; 57(23):10072-9. PubMed ID: 25375838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development.
    Thompson RA; Isin EM; Li Y; Weaver R; Weidolf L; Wilson I; Claesson A; Page K; Dolgos H; Kenna JG
    Chem Biol Interact; 2011 Jun; 192(1-2):65-71. PubMed ID: 21074519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A semi-automated method for measuring the potential for protein covalent binding in drug discovery.
    Day SH; Mao A; White R; Schulz-Utermoehl T; Miller R; Beconi MG
    J Pharmacol Toxicol Methods; 2005; 52(2):278-85. PubMed ID: 16125627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug bioactivation, covalent binding to target proteins and toxicity relevance.
    Zhou S; Chan E; Duan W; Huang M; Chen YZ
    Drug Metab Rev; 2005; 37(1):41-213. PubMed ID: 15747500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative assessment of reactive metabolite formation using 35S-labeled glutathione.
    Takakusa H; Masumoto H; Makino C; Okazaki O; Sudo K
    Drug Metab Pharmacokinet; 2009; 24(1):100-7. PubMed ID: 19252339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic activation in drug-induced liver injury.
    Leung L; Kalgutkar AS; Obach RS
    Drug Metab Rev; 2012 Feb; 44(1):18-33. PubMed ID: 21939431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical approaches to resolving reactive metabolite liabilities in early discovery.
    Dalvie D; Kalgutkar AS; Chen W
    Drug Metab Rev; 2015 Feb; 47(1):56-70. PubMed ID: 25410913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity.
    Takakusa H; Masumoto H; Yukinaga H; Makino C; Nakayama S; Okazaki O; Sudo K
    Drug Metab Dispos; 2008 Sep; 36(9):1770-9. PubMed ID: 18508880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Sakatis MZ; Reese MJ; Harrell AW; Taylor MA; Baines IA; Chen L; Bloomer JC; Yang EY; Ellens HM; Ambroso JL; Lovatt CA; Ayrton AD; Clarke SE
    Chem Res Toxicol; 2012 Oct; 25(10):2067-82. PubMed ID: 22931300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicophores: investigations in drug safety.
    Williams DP
    Toxicology; 2006 Sep; 226(1):1-11. PubMed ID: 16860917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships for thiol reactivity and rat or human hepatocyte toxicity induced by substituted p-benzoquinone compounds.
    Chan K; Jensen N; O'Brien PJ
    J Appl Toxicol; 2008 Jul; 28(5):608-20. PubMed ID: 17975849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detecting reactive drug metabolites for reducing the potential for drug toxicity.
    Grillo MP
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1281-302. PubMed ID: 26005795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.